SCHEDULE: Avoro Capital Discloses 3.15% Stake in MoonLake Immunotherapeutics
Beneficial Ownership Report
Avoro Capital Advisors LLC and Behzad Aghazadeh reported a 3.15% beneficial ownership stake in MoonLake Immunotherapeutics' Class A Ordinary Shares.
Summary
- Avoro Capital Advisors LLC and Behzad Aghazadeh (collectively, the "Reporting Persons") filed an Amendment No. 1 to Schedule 13G regarding their beneficial ownership in MoonLake Immunotherapeutics.
- The Reporting Persons beneficially own an aggregate of 2,000,000 Class A Ordinary Shares.
- This ownership represents 3.15% of the Class A Ordinary Shares outstanding.
- The percentage is calculated based on 63,501,402 Class A Ordinary Shares outstanding as of August 1, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q.
- The shares were acquired and are held for investment purposes in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 5
Explanation: Neutral, as this is a routine disclosure of beneficial ownership and does not contain operational or financial performance data. The investment itself could be seen as a positive signal by some, but the filing itself is purely factual.
Future Outlook
NA
Industry Context
This filing indicates a significant investment by Avoro Capital Advisors, an investment firm specializing in life sciences, in MoonLake Immunotherapeutics, a biotechnology company. Such investments reflect investor confidence or strategic positioning within the competitive biopharmaceutical landscape.
Stakeholder Impact
- Shareholders: Provides transparency regarding significant institutional ownership, potentially signaling confidence from a specialized life sciences investor.
Key Dates
| Date | Description |
|---|---|
| 2025-08-01 | Date as of which 63,501,402 Class A Ordinary Shares were outstanding, used for percentage calculation. |
| 2025-09-30 | Date of event which requires filing of this statement. |
| 2025-11-14 | Filing date of the Schedule 13G Amendment No. 1. |
Keywords
MoonLake Immunotherapeutics, Avoro Capital Advisors, Behzad Aghazadeh, Schedule 13G, Beneficial Ownership, Class A Ordinary Shares, Investment, SEC Filing, Biotechnology, Healthcare
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.